Shares of Tiziana Life Sciences Ltd. (TLSA) touched a 52-week high of $1.91 last week, marking a remarkable year-to-date increase of more than 170%.
This biotechnology company is focused on immunomodulation therapies for neuroinflammatory and neurodegenerative diseases, and its lead development candidate is intranasal Foralumab, a fully human, anti-CD3 monoclonal antibody.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com